Pharmicell (005690)

Currency in KRW
18,140
-710(-3.77%)
Closed·
005690 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17,76018,690
52 wk Range
8,15020,800
Key Statistics
Bid/Ask
18,130.00 / 18,140.00
Prev. Close
18,850
Open
18,500
Day's Range
17,760-18,690
52 wk Range
8,150-20,800
Volume
2.07M
Average Volume (3m)
1.4M
1-Year Change
70.8098%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
005690 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24,000
Upside
+32.30%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Pharmicell Company Profile

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Compare 005690 to Peers and Sector

Metrics to compare
005690
Peers
Sector
Relationship
P/E Ratio
0.0x−7.6x−0.6x
PEG Ratio
0.00−0.090.00
Price/Book
0.0x2.5x2.6x
Price / LTM Sales
0.0x14.3x3.3x
Upside (Analyst Target)
0.0%6.9%45.0%
Fair Value Upside
Unlock7.8%6.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24,000
(+32.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 06, 2023
EPS / Forecast
-2.56 / --
Revenue / Forecast
11.93B / 17.80B
EPS Revisions
Last 90 days

005690 Income Statement

FAQ

What Is the Pharmicell (005690) Stock Price Today?

The Pharmicell stock price today is 18 140

What Stock Exchange Does Pharmicell Trade On?

Pharmicell is listed and trades on the Seoul Stock Exchange.

What Is the Stock Symbol for Pharmicell?

The stock symbol for Pharmicell is "005690."

What Is the Pharmicell Market Cap?

As of today, Pharmicell market cap is 1,13T.

What Is Pharmicell's Earnings Per Share (TTM)?

The Pharmicell EPS (TTM) is -614.

When Is the Next Pharmicell Earnings Date?

Pharmicell will release its next earnings report on Mar 24, 2026.

From a Technical Analysis Perspective, Is 005690 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Pharmicell Stock Split?

Pharmicell has split 5 times.

What is the current trading status of Pharmicell (005690)?

As of Feb 24, 2026, Pharmicell (005690) is trading at a price of 18 140, with a previous close of 18 850. The stock has fluctuated within a day range of 17 760 to 18 690, while its 52-week range spans from 8 150 to 20 800.

What Is Pharmicell (005690) Price Target According to Analysts?

The average 12-month price target for Pharmicell is KRW24 000, with a high estimate of KRW24000 and a low estimate of KRW24000. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +32,30% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.